Chronic pain syndromes of neuropathic, nociceptive and mixed origins cause substantial human suffering and disability. Despite the number of pain therapies marketed in the U.S., there remains an unfilled need for drugs that provide improved efficacy, safety and tolerability. Branded reformulations and fixed-dose combinations of previously marketed active molecules provide increased convenience, safety and tolerability for patients; however, health plans often have difficulty gauging the value of these qualities, especially when efficacy is equivalent, compared with the lower cost-burden of generic alternatives. Further, the subjective nature of assessing pain outcomes, compared with other conditions that are monitored by laboratory testing and imaging, and increasing brand crowding within the pain market means that marketers bear a greater responsibility to differentiate the value of their drug to health plans in order to receive widespread reimbursement.

Using tiering and restrictions data from Fingertip Formulary, as well as insight from 47 pharmacy directors, this report determines the key trends in reimbursement of analgesics for chronic pain, drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to steal share from the competition and provides insight for stakeholders looking to capitalize on future shifts in coverage in order to better position their products among competitors.

Related Reports

Formulary Advantages in Type 2 Diabetes:Rebates and discounts dictate the formulary position of branded therapies among some U.S. health plans.

According to the Centers for Disease Control and Prevention (CDC), an estimated 25.8 million people in the United States have diabetes. Diabetes is the leading cause of kidney failure, nontraumatic lo...

View Details

Formulary Advantages in Atrial Fibrillation: How Will MCO Size Affect the Design of Factor Xa Formularies?

In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging facto...

View Details

Formulary Advantages in Asthma and COPD Therapies: Formulary Advantages in Asthma and COPD Therapies - Abstract

The market for asthma and chronic obstructive pulmonary disease (COPD) has grown notably in recent years because of increasing prevalence and diagnosis rates for both conditions as well as the greater...

View Details

Formulary Advantages in Psychiatric Drugs: Medicare plans readily employ cost-sharing measures and formulary restrictions to direct early use of generics and preferred brands for psychiatry.

According to the National Institute of Mental Health, each year tens of millions of Americans are affected by mental illness. Although significant strides have been made toward understanding the patho...

View Details